Stay updated with breaking news from Limitations Associated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The "Global Stem Cell Manufacturing Market by Product (Consumables, Instrument, HSCs, MSCs, iPSCs, ESCs), Application (Research, Clinical (Autologous, Allogenic), Cell & Tissue Banking), End-user (Pharma & Biotech, Hospitals, Tissue Bank), and Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
Message : Required fields DEERFIELD, Ill., May 10, 2021 (GLOBE NEWSWIRE) -- Surgalign Spine Technologies, (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today reported operating results for the first quarter of 2021. Highlights: Total global spine revenue of $23.3 million, compared to $27.1 million in the first quarter of 2020 Net loss from continuing operations of $15.2 million inclusive of approximately $3.2 million of non-recurring charges Adjusted EBITDA loss of $9.8 million, compared to a loss of...
Gross profit decreased $1.7 million to $79.7 million. Gross margin decreased to 75.5% compared to 77.7% in the prior year period. Net loss was $(5.8) million, or $(0.30) per share, compared to net income of $25.7 million, or $1.32 per share in the prior year period. Adjusted net income was $3.4 million, or $0.17 per share, compared to adjusted net income of $1.7 million, or $0.09 per share in the prior year period. EBITDA was $1.8 million, compared to $12.4 million in the prior year period. Adjusted EBITDA was $14.0 million, or 13.3% of net sales, compared to $11.4 million, or 10.9% of net...